{"id":49021,"date":"2025-11-26T13:30:34","date_gmt":"2025-11-26T05:30:34","guid":{"rendered":"https:\/\/flcube.com\/?p=49021"},"modified":"2025-11-26T13:30:35","modified_gmt":"2025-11-26T05:30:35","slug":"novos-kyinsu-wins-eu-approval-for-type-2-diabetes-a-once-weekly-combo-first","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49021","title":{"rendered":"Novo&#8217;s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First"},"content":{"rendered":"\n<p><strong>Novo Nordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced that the <strong>European Commission (EC)<\/strong> has granted marketing authorization for <strong>Kyinsu<\/strong> (once\u2011weekly IcoSema), a fixed\u2011ratio combination of basal insulin icodec and GLP\u20111 RA semaglutide, as an adjunct to diet and exercise for adults with <strong>Type\u202f2 Diabetes Mellitus<\/strong> inadequately controlled on basal insulin or GLP\u20111 therapy, based on the <strong>COMBINE Phase\u202fIIIa trial program<\/strong> demonstrating superior HbA1c reduction vs. individual components.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Kyinsu (IcoSema) \u2013 once\u2011weekly insulin icodec + semaglutide<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Novo Nordisk A\/S (NYSE: NVO)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing authorization (first\u2011in\u2011class once\u2011weekly combo)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Type\u202f2 diabetes adjunct to diet\/exercise + oral glucose\u2011lowering drugs<\/td><\/tr><tr><td><strong>Trial Basis<\/strong><\/td><td>COMBINE Phase\u202fIIIa program (3 trials)<\/td><\/tr><tr><td><strong>Key Results<\/strong><\/td><td>Superior HbA1c reduction vs. components; non\u2011inferior to basal\u2011bolus insulin; greater weight loss; lower hypoglycemia<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Commercial rollout Q1\u202f2026; U.S. FDA filing planned H1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Fixed\u2011ratio combination of <strong>once\u2011weekly basal insulin icodec<\/strong> and <strong>once\u2011weekly GLP\u20111 receptor agonist semaglutide<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>First and only once\u2011weekly<\/strong> injection combining basal insulin + GLP\u20111 RA, reducing injection frequency from daily to weekly<\/li>\n\n\n\n<li><strong>Dosing:<\/strong> Single subcutaneous injection vs. separate daily basal insulin + weekly GLP\u20111 or multiple daily basal\u2011bolus injections<\/li>\n\n\n\n<li><strong>Clinical Benefits:<\/strong> <strong>Superior glycemic control<\/strong>, <strong>pronounced weight loss<\/strong>, <strong>lower severe hypoglycemia rate<\/strong> vs. basal\u2011bolus regimen<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-combine-program\">Clinical Evidence \u2013 COMBINE Program<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Kyinsu (IcoSema)<\/th><th>Comparator<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>HbA1c reduction<\/strong><\/td><td>Once\u2011weekly combo<\/td><td>Individual components<\/td><td><strong>Superior<\/strong><\/td><\/tr><tr><td><strong>HbA1c vs basal\u2011bolus<\/strong><\/td><td>Once\u2011weekly combo<\/td><td>Daily basal\u2011bolus insulin<\/td><td><strong>Non\u2011inferior<\/strong><\/td><\/tr><tr><td><strong>Weight change<\/strong><\/td><td>Once\u2011weekly combo<\/td><td>Basal\u2011bolus insulin<\/td><td><strong>Greater weight loss<\/strong><\/td><\/tr><tr><td><strong>Severe hypoglycemia<\/strong><\/td><td>Once\u2011weekly combo<\/td><td>Basal\u2011bolus insulin<\/td><td><strong>Lower rate<\/strong><\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Well\u2011tolerated<\/td><td>Consistent with components<\/td><td><strong>Favorable profile<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Type 2 Diabetes Market<\/strong><\/td><td>$45\u202fbillion (2024)<\/td><\/tr><tr><td><strong>EU Type 2 Diabetes Patients<\/strong><\/td><td>~60\u202fmillion diagnosed<\/td><\/tr><tr><td><strong>Basal\u2011Insulin\u2011Treated Population<\/strong><\/td><td>~35% of patients (21\u202fmillion)<\/td><\/tr><tr><td><strong>GLP\u20111\u2011Treated Population<\/strong><\/td><td>~15% of patients (9\u202fmillion)<\/td><\/tr><tr><td><strong>Peak Sales Forecast (Kyinsu)<\/strong><\/td><td><strong>\u20ac3.5\u20114.5\u202fbillion<\/strong> (US$3.8\u20114.9\u202fbillion) EU peak by 2032<\/td><\/tr><tr><td><strong>Pricing<\/strong><\/td><td>Expected 20\u201130% premium over separate component therapy<\/td><\/tr><tr><td><strong>Competition:<\/strong> <strong>Novo\u2019s own Ozempic + Tresiba<\/strong> (separate injections); <strong>Lilly\u2019s Mounjaro<\/strong> (GLP\u20111 only); <strong>Sanofi\u2019s Soliqua<\/strong> (daily insulin\/GLP\u20111 combo)<\/td><td><\/td><\/tr><tr><td><strong>Advantage:<\/strong> Once\u2011weekly dosing addresses <strong>patient convenience<\/strong> and <strong>adherence<\/strong>, critical in chronic disease management<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reimbursement Path:<\/strong> EC approval triggers national pricing negotiations; expected <strong>broad reimbursement<\/strong> given Novo\u2019s established payer relationships<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Leverages existing <strong>semaglutide<\/strong> and <strong>icodec<\/strong> production capacity; minimal incremental capex required<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> U.S. FDA submission <strong>H1\u202f2026<\/strong>; filing in China (world\u2019s largest diabetes market) expected <strong>H2\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Kyinsu\u2019s commercial launch, market penetration, and global regulatory pathway. Actual results may differ materially due to risks including pricing negotiations, competitive responses, and real\u2011world adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) announced that the European Commission (EC) has granted marketing authorization&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49022,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,148,860,15],"class_list":["post-49021","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-novo-nordisk","tag-nyse-nvo","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo&#039;s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced that the European Commission (EC) has granted marketing authorization for Kyinsu (once\u2011weekly IcoSema), a fixed\u2011ratio combination of basal insulin icodec and GLP\u20111 RA semaglutide, as an adjunct to diet and exercise for adults with Type\u202f2 Diabetes Mellitus inadequately controlled on basal insulin or GLP\u20111 therapy, based on the COMBINE Phase\u202fIIIa trial program demonstrating superior HbA1c reduction vs. individual components.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49021\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo&#039;s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced that the European Commission (EC) has granted marketing authorization for Kyinsu (once\u2011weekly IcoSema), a fixed\u2011ratio combination of basal insulin icodec and GLP\u20111 RA semaglutide, as an adjunct to diet and exercise for adults with Type\u202f2 Diabetes Mellitus inadequately controlled on basal insulin or GLP\u20111 therapy, based on the COMBINE Phase\u202fIIIa trial program demonstrating superior HbA1c reduction vs. individual components.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49021\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T05:30:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T05:30:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49021#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49021\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo&#8217;s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First\",\"datePublished\":\"2025-11-26T05:30:34+00:00\",\"dateModified\":\"2025-11-26T05:30:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49021\"},\"wordCount\":465,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49021#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2601.webp\",\"keywords\":[\"Diabetes\",\"Novo Nordisk\",\"NYSE: NVO\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49021#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49021\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49021\",\"name\":\"Novo's Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49021#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49021#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2601.webp\",\"datePublished\":\"2025-11-26T05:30:34+00:00\",\"dateModified\":\"2025-11-26T05:30:35+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) announced that the European Commission (EC) has granted marketing authorization for Kyinsu (once\u2011weekly IcoSema), a fixed\u2011ratio combination of basal insulin icodec and GLP\u20111 RA semaglutide, as an adjunct to diet and exercise for adults with Type\u202f2 Diabetes Mellitus inadequately controlled on basal insulin or GLP\u20111 therapy, based on the COMBINE Phase\u202fIIIa trial program demonstrating superior HbA1c reduction vs. individual components.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49021#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49021\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49021#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2601.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo's Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49021#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo&#8217;s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo's Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) announced that the European Commission (EC) has granted marketing authorization for Kyinsu (once\u2011weekly IcoSema), a fixed\u2011ratio combination of basal insulin icodec and GLP\u20111 RA semaglutide, as an adjunct to diet and exercise for adults with Type\u202f2 Diabetes Mellitus inadequately controlled on basal insulin or GLP\u20111 therapy, based on the COMBINE Phase\u202fIIIa trial program demonstrating superior HbA1c reduction vs. individual components.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49021","og_locale":"en_US","og_type":"article","og_title":"Novo's Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First","og_description":"Novo Nordisk A\/S (NYSE: NVO) announced that the European Commission (EC) has granted marketing authorization for Kyinsu (once\u2011weekly IcoSema), a fixed\u2011ratio combination of basal insulin icodec and GLP\u20111 RA semaglutide, as an adjunct to diet and exercise for adults with Type\u202f2 Diabetes Mellitus inadequately controlled on basal insulin or GLP\u20111 therapy, based on the COMBINE Phase\u202fIIIa trial program demonstrating superior HbA1c reduction vs. individual components.","og_url":"https:\/\/flcube.com\/?p=49021","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-26T05:30:34+00:00","article_modified_time":"2025-11-26T05:30:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49021#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49021"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo&#8217;s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First","datePublished":"2025-11-26T05:30:34+00:00","dateModified":"2025-11-26T05:30:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49021"},"wordCount":465,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49021#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601.webp","keywords":["Diabetes","Novo Nordisk","NYSE: NVO","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49021#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49021","url":"https:\/\/flcube.com\/?p=49021","name":"Novo's Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49021#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49021#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601.webp","datePublished":"2025-11-26T05:30:34+00:00","dateModified":"2025-11-26T05:30:35+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) announced that the European Commission (EC) has granted marketing authorization for Kyinsu (once\u2011weekly IcoSema), a fixed\u2011ratio combination of basal insulin icodec and GLP\u20111 RA semaglutide, as an adjunct to diet and exercise for adults with Type\u202f2 Diabetes Mellitus inadequately controlled on basal insulin or GLP\u20111 therapy, based on the COMBINE Phase\u202fIIIa trial program demonstrating superior HbA1c reduction vs. individual components.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49021#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49021"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49021#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601.webp","width":1080,"height":608,"caption":"Novo's Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49021#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo&#8217;s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49021"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49021\/revisions"}],"predecessor-version":[{"id":49023,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49021\/revisions\/49023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49022"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}